Pharmacist-managed telephone clinic review of antidementia medication effectiveness

Consultant Pharmacist

Volumn 26, Issue 4, 2011, Pages 264-272

  Oderda, Lynda ^a,b   Holman, Christine ^b   Nichols, Ben ^b   Rupper, Randall ^c,d,e   Bair, Byron ^e,f   Hoffman, Matthew ^e   Hicken, Bret ^f  

^a UNIVERSITY OF UTAH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Veterans Rural Health Resource Center Western Region   (United States)

^d GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f VASLCHCS   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Antidementia medications; Combination therapy; Dementia; Geriatric; Medication discontinuation; N methyl D aspartate receptor antagonist; Veteran

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE;

ARTICLE; CAREGIVER; COGNITION; DEMENTIA; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; HEALTH CARE PERSONNEL; HUMAN; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACIST; TELEMEDICINE; TREATMENT RESPONSE;

AMBULATORY CARE; DEMENTIA; HUMANS; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; PHARMACEUTICAL SERVICES; PHARMACISTS; TELEPHONE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 80051574898     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2011.264     Document Type: Article

References (18)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44.
2. Alzheimers Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6:158-94.
3. Alzheimers Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009;5:234-70.
4. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-97. (Pubitemid 351665469)
5. Qaseem A, Snow V, Cross JT Jr. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370-8.
6. Gill SS, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009;169:867-73.
7. Lanctôt KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64. (Pubitemid 37174596)
8. Trinh NH, Hoblyn J, Mohanty S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289:210-6. (Pubitemid 36068709)
9. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease. Ann Pharmacother 1999;33:441-50. (Pubitemid 29215811)
10. Milne A, Culverwell A, Guss R et al. Screening for dementia in primary care: a review of the use, efficacy, and quality of measures. Int Psychogeriatr 2008;20:911-26.
11. Porsteinsson AP, Grossberg GT, Mintzer J et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9. (Pubitemid 351536358)
12. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24. (Pubitemid 38101604)
13. Aricept package insert. 2010. Accessed October 22, 2010. Available at http://www.aricept.com/pdf/AriceptComboFullPIJuly2010.pdf.
14. About rural veterans. 2006. Accessed July 30, 2010. Available at http://www.ruralhealth.va.gov/RURALHEALTH/About-Rural-Veterans.asp.
15. Aricept. 2009. Accessed June 28, 2010. Available at http://www. accessdata.fda.gov/drugsatfda-docs/label/2006/020690s026,021720s003lbl.pdf.
16. Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007;19:421-56. (Pubitemid 46707434)
17. Namenda package insert. 2010. Accessed June 4, 2010. Available at http://www.frx.com/pi/Namenda-pi.pdf.
18. Chodosh J, Petitti DB, Elliott M et al. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 2004;52:1051-9. (Pubitemid 38869062)